Usually, yes. Cigna, Aetna and UnitedHealthcare cover balloon sinus dilation for chronic or recurrent sinusitis when the record shows qualifying symptoms, a failed medication trial of at least 8 weeks under Cigna’s policy, and CT disease in each sinus treated. Medicare has no national or local coverage policy, so the medical record decides payment.
Payers have mostly stopped arguing that balloon dilation does not work, and practices that still appeal on clinical evidence are fighting the wrong battle. The denials we see are about sequence and scope: in our audit the CT scan predated the completed medication trial on 22% of denied balloon dilation claims. A scan taken before the trial ends cannot show that the trial failed, and no appeal letter fixes a timeline.
Methodology:Figures come from the Luxen claim audit, 61,400 claims audited, Jan 2025 to Jun 2026, including 5,200 ENT claims; Luxen billing reviews, 410 practice billing reviews, Jan 2025 to Jun 2026; and Luxen client data, 38 client practices, Jan 2024 to Jun 2026. Payment amounts are 2026 Medicare national rates from the CMS final rule addenda.
Balloon sinuplasty is covered by most commercial plans and by Medicare when the record proves three things in order: qualifying symptoms, a failed medication trial, and CT evidence of disease in each sinus treated. Payers rarely argue anymore about whether the procedure works. They argue about whether this chart, for this sinus, meets the written criteria. This page sets out those criteria payer by payer, the codes and 2026 rates, and the documentation gaps behind most denials.
Yes, for chronic rhinosinusitis and recurrent acute rhinosinusitis that meet a payer’s criteria, and not for most other indications. Cigna, Aetna and UnitedHealthcare all publish medical necessity criteria for balloon sinus ostial dilation, and all three treat it as a covered option when those criteria are met. None of them covers it on the surgeon’s judgment alone.
The criteria are not identical. Cigna’s policy 0480 requires at least two qualifying symptoms lasting more than three consecutive months, CT evidence of disease in each sinus being treated, and failure of at least eight weeks of medical therapy covering antibiotics, a steroid spray, an antihistamine spray or decongestant, and saline irrigation. UnitedHealthcare’s Sinus Surgeries and Interventions policy sets the symptom threshold at longer than 12 weeks and adds a timing rule: the CT has to be taken after medical therapy is complete. Aetna’s CPB 0937 covers dilation for uncomplicated sinusitis without nasal polyposis and lists more than a dozen indications it considers experimental.
Medicare covers it, but without a written policy to point to. There is no National Coverage Determination for balloon sinus ostial dilation, and no Local Coverage Determination or billing article either, which UnitedHealthcare states plainly in its Medicare Advantage policy. Traditional Medicare contractors therefore judge each claim on whether the service was reasonable and necessary, and the medical record carries the whole argument if the claim is reviewed.
Medicare Advantage plans fill the gap themselves. Federal rules let an MA plan apply internal coverage criteria when Medicare’s own criteria are not fully established, provided the plan publishes the criteria and the evidence behind them. UnitedHealthcare’s Medicare Advantage policy simply points to its commercial criteria. In practice, an MA patient is held to roughly the same checklist as a commercial patient, often with prior authorization attached.
Some plans still label stand-alone dilation experimental or investigational, and plans that cover the procedure overall label specific uses that way. Aetna considers a repeat balloon procedure in any sinus, isolated ethmoid disease, nasal polyposis of grade 2 or greater and unilateral pansinus opacification experimental. The American Academy of Otolaryngology Head and Neck Surgery (AAO-HNS) published a statement in April 2021 opposing experimental labels on stand-alone dilation, which is useful in an appeal when a plan’s policy conflicts with its own published criteria or with current evidence.
Payers require proof of the diagnosis, proof that medication failed, and imaging that shows disease in the exact sinus being dilated, documented in that order. The list below is the set we check before a request goes out, built from Cigna 0480, Aetna CPB 0937 and UnitedHealthcare’s policy. Requests are prepared and tracked through our eligibility and prior authorization workflow.
The sequence matters as much as the content. In the ENT claims we audit, the CT scan predated the completed medication trial on 22% of denied balloon dilation claims, and the medication trial was documented without dates or durations on 34% of balloon dilation claims we audited. Both are fixable before the request is sent, and neither is fixable after.
Balloon dilation is reported with four codes, and none of them can be billed with surgery on the same sinus. 31295 covers the maxillary ostium, 31296 the frontal, 31297 the sphenoid, and 31298 the frontal and sphenoid ostia together. The codes are unilateral, fluoroscopy is included when used, and the diagnostic nasal endoscopy code 31231 is bundled into any surgical endoscopy at the same encounter.
AAO-HNS coding guidance sets the same-sinus pairs. 31295 is not reported with 31233, 31256 or 31267 on the same sinus, 31296 is not reported with 31276, and 31297 is not reported with 31235, 31287 or 31288. Ethmoidectomy works differently: 31254 or 31255 is reported in addition to the dilation code. If tissue is removed after dilation, report the resection code and drop the balloon. Cigna and Aetna apply the same logic to payment, treating dilation used during FESS in the same sinus as part of the primary procedure.
A balloon dilation code was paired with a resection code on the same sinus on 7% of claims combining the two in our audit, inside a wider pattern where coding and modifier errors caused 21% of denials. Our medical coding review checks the sinus and side on every line before the claim goes out.
The 2026 Medicare national rates show why office dilation is a different business from facility dilation. In the office, the surgeon is paid $1,579 for 31295, $1,604 for 31296, $1,566 for 31297 and $2,968 for 31298. In a facility the same codes pay the surgeon $135, $152, $124 and $216.
The gap is the device. The office rate carries the balloon system in its practice expense, so an office claim denied in full loses the cost of the device as well as the professional fee. Our otolaryngology billing page covers the wider ENT code set, including nasal endoscopy and modifier 25 on scope days.
The site of service changes the total cost of the same case by more than double. For one 31298 case at 2026 Medicare national rates, the hospital outpatient department is paid $7,210 and the surgeon $216, a total of $7,426. An ambulatory surgery center is paid $2,451 plus the same $216, a total of $2,667. In the physician office the total is the surgeon’s $2,968.
All four dilation codes map to the same hospital outpatient payment group, APC 5155, so a single-sinus maxillary case costs the hospital outpatient benefit as much as a frontal and sphenoid case. When a case is booked in a hospital outpatient department, the record should say why the office or an ASC was not suitable, because the payer can see the same arithmetic.
For a Medicare patient treated in the office for 31298, the 20% coinsurance on $2,968 is $593.60, plus any unmet Part B deductible. Commercial patients pay according to their deductible and coinsurance, which is why the same procedure can cost one patient a few hundred dollars and another several thousand. Quote the patient from the allowed amount on their plan, not from a price range on a marketing page.
Most balloon dilation denials trace to the medical record rather than the code. Across the denied balloon dilation claims in our audit, medical necessity records caused 38% of denials, authorization gaps 29%, same-sinus coding conflicts 17%, and eligibility and other causes 16%.
The authorization problem is specific to this procedure. Because coverage runs sinus by sinus, an approval can be valid and still not match the claim: 13% of balloon dilation claims billed a sinus that was not on the authorization. Across all specialties, missing or invalid prior authorization caused 17% of denials and eligibility and coverage errors caused 24%, so balloon dilation sits at the authorization-heavy end of the range.
Take a three-surgeon ENT group performing 10 office maxillary dilations (31295 at $1,579) and 6 office frontal and sphenoid dilations (31298 at $2,968) a month. That is $15,790 plus $17,808, or $33,598 a month in allowed charges at Medicare national rates, from dilation alone.
Even the recovered money arrives late. Median appeal turnaround was 34 days from filing to payer decision, so a denied office case waits more than a month for cash the practice has already spent on a device. The cheaper fix sits upstream: a request that carries a dated medication history, a post-trial CT with sinus-by-sinus findings, and an approval that matches the claim line for line.
Appeal on the payer’s own criteria, line by line. Quote the policy number and effective date, map each criterion to a dated page in the record, attach the CT report and the medication log, and request a peer-to-peer review when the denial says the record did not establish medical necessity. Where a plan calls stand-alone dilation experimental, attach the AAO-HNS reimbursement statement. The wider appeal process is covered in our guide to claim denial reasons and appeals.
Whether this work stays in house is a volume question. A practice doing a handful of dilations a year can run the checklist above by hand. A rhinology practice doing several a week needs someone who owns every authorization, matches it to the claim, and works each denial within days rather than months. Fully loaded in-house billing cost 7.9% of collections for practices under $2M, across 96 practices that shared payroll data, against 3% to 6% of collections for outsourced billing. Our denials and AR recovery team works this queue, and full-service medical billing covers the whole cycle inside your existing system. For a read on your own balloon claims, start with a free billing review.
Want to know how this applies to your practice? We will review your AR and denials, free, in 30 minutes.
Book the reviewThe plans agree on the shape of the requirement and differ on the details that decide a request. Read the current version before each request, because all three commercial policies carry 2026 effective or review dates.
| Requirement | Cigna 0480 | Aetna CPB 0937 | UnitedHealthcare | Traditional Medicare |
|---|---|---|---|---|
| Written policy | Yes, effective April 15, 2026 | Yes, reviewed April 10, 2026 | Sinus Surgeries and Interventions, 2026 | No NCD, LCD or billing article |
| Chronic symptoms | 2 or more, over 3 consecutive months | Uncomplicated sinusitis without polyps, criteria in policy appendix | Longer than 12 weeks | Reasonable and necessary standard |
| Medical therapy | At least 8 weeks of antibiotics, steroid spray, antihistamine spray or decongestant, and saline | Set in policy appendix | Full courses of steroids, antibiotics if bacterial infection suspected, and irrigation | Must be documented in the record |
| CT | Disease in each sinus treated | Set in policy appendix | After therapy, within 12 months, extent stated for each sinus, same side as symptoms | Supports necessity on review |
| Recurrent acute disease | 4 or more episodes a year, endoscopy findings, CT ostial occlusion | Acute maxillary, frontal and sphenoid codes covered when criteria met | 4 or more episodes a year with symptom-free intervals, CT findings | Same standard |
| Same sinus as FESS | Not separately reimbursable | Part of the primary procedure | CPT and NCCI same-sinus rules | CPT and NCCI same-sinus rules |
| Key exclusions | All other indications | Polyps grade 2 or more, isolated ethmoid disease, repeat balloon, unilateral pansinus opacification | Sinonasal polyps or tumors | None published |
Medicare Advantage plans may publish their own criteria under federal rules, and UnitedHealthcare’s Medicare Advantage policy applies its commercial criteria, so an MA request should be built to the commercial column for that plan.
Balloon dilation is billed almost entirely by otolaryngology, but the evidence it depends on is often created by other specialties. Dental, physical therapy, behavioral health and ambulance practices do not bill these codes.
The office suite is where the money and the risk sit together. 31298 pays $2,968 in the office against $216 in a facility, and a full denial on an office case loses the device cost along with the fee. Build the authorization request around the claim you intend to send: each sinus, each side, and 31298 rather than 31296 plus 31297 when the frontal and sphenoid ostia are dilated together. Keep the post-trial CT report and the dated medication log in one place in the chart, because every payer asks for both and every appeal needs them. When dilation and resection share a session, our breakdown of sinus surgery bundling and modifier 50 covers which lines can stand together.
Much of the medication trial lives in allergy records: steroid sprays, antihistamine sprays, irrigation and immunotherapy. Cigna counts at least eight weeks across these agents, and a referral note that says the patient failed medical therapy will not satisfy it. Referral letters should list each agent with start and stop dates and the response. Allergy practices that also bill testing and immunotherapy will find the coding rules on our allergy and immunology billing page.
Primary care usually prescribes the antibiotic courses and sees the acute episodes. For recurrent acute rhinosinusitis, Cigna and UnitedHealthcare require four or more episodes a year, and the dated visit notes from primary care are the only proof. Acute sinusitis visits coded with the specific sinus, such as J01.00 for acute maxillary sinusitis, make that record usable later. See primary care billing for visit coding.
ASC payment varies more by code than the physician rates do. In 2026 the national ASC rate is $3,105 for 31295, $1,496 for 31296, $3,113 for 31297 and $2,451 for 31298, so the combined frontal and sphenoid code pays the facility less than a single maxillary dilation. The facility claim and the surgeon claim must carry the same codes and sides, and the authorization should name the ASC as the site. See ambulatory surgery center billing.
All four dilation codes map to APC 5155 with status indicator J1, paying $7,210 nationally in 2026 for any of the four codes. That price is why hospital cases draw scrutiny. Document why the case needed a hospital setting, such as anesthesia needs or comorbidities, and confirm the authorization covers the hospital site rather than the office. See hospital billing.
Medicare Advantage plans often do, and they may apply their own published criteria because Medicare has no national or local coverage policy for balloon dilation. Traditional Medicare decides these claims on the reasonable and necessary standard, so the record carries the case if a claim is reviewed. Check the patient’s plan before scheduling, and document symptoms, the medication trial and CT findings either way.
Yes, on different sinuses. A balloon code cannot be billed with a resection code on the same sinus, and Cigna and Aetna treat dilation used during FESS in that sinus as part of the primary procedure. Ethmoidectomy codes 31254 and 31255 are reported in addition to a dilation code. If tissue is removed after dilation, report the resection code instead.
Often not. Aetna considers a repeat balloon procedure in any sinus, or a history of failed balloon dilation in the sinus to be treated, experimental and investigational. Other plans may handle revision under their sinus surgery criteria instead. If a sinus needs more treatment after dilation, check whether the plan expects endoscopic sinus surgery rather than a second balloon, and request approval on that basis.
UnitedHealthcare treats a CT as recent when it is performed within 12 months of the planned procedure, and requires it to be taken after medical therapy is complete. The report should name each diseased sinus and state the extent of disease as percentage opacification or a modified Lund-Mackay score. Cigna requires CT evidence of disease in every sinus being treated.
Aetna lists chronic maxillary, frontal and sphenoidal sinusitis, J32.0, J32.1 and J32.3, and the matching acute codes as covered when criteria are met. Chronic ethmoidal sinusitis, J32.2, is listed as not covered for balloon dilation, which matches the rule that isolated ethmoid disease does not qualify. Code the sinus actually dilated, and keep laterality consistent with the CT.
Usually not. Aetna considers dilation experimental for nasal polyposis of grade 2 or greater, and UnitedHealthcare lists sinonasal polyps as unproven and not medically necessary. Cigna’s criteria differ and accept polyposis among the CT findings for chronic disease. Patients with polyps are more often treated with endoscopic sinus surgery, so check the policy before requesting dilation.
A free 30 minute review of your AR ageing and denial reasons. We tell you what is recoverable and what it would take. No deck, no commitment, no fee.
Book a free billing review